Immune Network Research News

David G.M. Smith dgmsmith at DIRECT.CA
Sat Feb 24 13:41:50 EST 1996

The INR News
Recent Progress at Immune Network Research Ltd.
February 22, 1996

Public Listing

Immune Network Research Ltd. (INR) is on the verge of becoming a =

publicly trading company.  On January 10, 1996 the Vancouver Stock =

Exchange (=93VSE=94) approved the Pre-Listing Application document for the =

amalgamation with Bobby Cadillac s Food Corporation.  For the initial =

financing of the Company, Yorkton Securities Inc. has submitted a =

Statement of Material Facts document (=93SMF=94) to the Exchange for their =

review.  Approval of the SMF is imminent, and we expect to be trading =

very soon.

Web Site =

INR announces that the Company has established an Internet World Wide =

Web Site at the Internet address: =  We invite you to connect to =

our new Internet Web site where the Company s background, scientific =

research, and corporate profile, as well as medical information on =

HIV/AIDS, and interactive E-mail response are available.  Our site is =

also linked to comprehensive information on HIV/AIDS.


We have completed production of the monoclonal material and the =

identification of suitable macaque monkeys and have begun =

safety/feasibility trials of our CTB-1 product, a monoclonal antibody =

that appears to block the killing of helper T cells by killer T cells =

which manifests in AIDS patients.  This very important study for INR is =

being conducted in collaboration with Dr. Norman Letvin, one of the =

world s leading experts in animal models of AIDS, at Harvard University.


Under the network theories postulated by Dr. Geoffrey Hoffmann this =

fundamental work may lead to both an AIDS vaccine and a therapeutic.  =

Research on the elimination of HIV-specific T cells is in progress with =

very encouraging preliminary results.  The basic premise that only a =

small proportion of T cells in the blood directly bind to the protein =

that is known as the V3 loop of HIV has been demonstrated in our =

laboratory at the University of British Columbia.  This important result =

fits well with the predictions under the theory that HIV preferentially =

infects and replicates in HIV- specific T4 cells, and that elimination =

of those HIV-specific cells is central to a treatment and a vaccine for =

the disease.

Monoclonal Antibodies Contract

A non-exclusive contract to sell some of INR s monoclonal antibodies was =

recently signed with Serotec Inc., an international distributor of =

research products.  We are pleased to announce that INR s antibodies =

have been included in Serotec s 1996 catalogue, and thus are available =

to scientists in North America and Europe.  The sale of antibodies is =

expected to generate significant revenue for the Company.  In addition, =

scientists from INR obtained a grant from the Industry Research =

Assistance Program (=93IRAP=94) to produce new monoclonal antibodies for =


INR Scientist Receives National Recognition

Dr. Michael D. Grant, Director and Associate Scientist of INR, has been =

appointed to the NHRDP-MRC Biomedical/Clinical AIDS Research Review =

Committee.  This committee reviews and makes recommendations for funding =

of AIDS research grants submitted to the NHRDP or MRC.  This appointment =

recognizes Dr. Grant s contributions to AIDS research, and highlights =

his stature as an expert in the field.  Congratulations!

=0CINR in the Forefront of HIV Research

The isolation of chemicals produced by the immune system that stop the =

growth of HIV was recently announced by scientists in the United States =

and Germany.  Dr. Ana Maria Gomez, President and Senior Scientist of =

INR, was involved in the study of T8 cells that produce these substances =

while working at McMaster University.  Although INR is not directly =

involved in the study of inhibitory T8 cells, the Company s approach to =

the study of HIV is also immunologic.  Dr. Gomez is using expertise =

acquired during four years of studying these inhibitory cells to study =

the role of other populations of T cells in HIV infected individuals.  =

INR s objective is to use its scientists  unique knowledge of the immune =

system to come up with innovative ways to treat and prevent HIV =

infection and AIDS.  The potential for the success of this approach is =

illustrated by the fact that there are individuals who have been =

infected with HIV for more than five years, but show no ill effects from =

their infection.  This means that the immune system can successfully =

control the virus.  This notion is further confirmed by the fact that =

there are also individuals who appear to be resistant to HIV infection, =

including a group of prostitutes from Kenya, who are being studied by an =

international collaborative group headed by Dr. Francis Plummer of the =

University of Manitoba (see below).

Agreement with Dr. Francis Plummer

The Company is expecting to sign an agreement with the international =

collaborative group studying HIV-resistant individuals in Nairobi, =

Kenya.  The group is headed by Dr. Francis Plummer, an infectious =

diseases physician and an internationally recognized expert in HIV/AIDS, =

and includes scientists from the University of Manitoba, University of =

Nairobi, University of Toronto, McMaster University, Oxford University, =

and the US National Institute of Health.  This agreement is a very =

important step for INR, as it will provide the Company with this =

opportunity to study this group of resistant individuals who probably =

hold the key to an effective vaccine against HIV.

Agreement with Dr. George Spitalny

INR has received and signed a letter of intent to enter into an =

agreement with Dr. George Spitalny, a senior biochemist with experience =

in the pharmaceutical industry.  The letter provides for INR, once the =

financing is completed, to enter into a formal agreement for access to =

drug delivery technology with very wide potential application, including =

cancer chemotherapy.  Dr. Spitalny will develop one or more products for =

targeted drug delivery; this means that a therapeutic product could be =

taken through clinical testing and FDA Phase II trials within two years.

For Corporate & Investor Information Please Call:  Mr. Leon Frank =

Anderson or Mr. Bing Jung
Telephone:  604-687-8532		Facsimile:  604-683-8125


Dr. Ana Maria Gomez, President	Dr. Geoffrey W. Hoffmann
Ms. Catherine Knight, Corporate Secretary	Chief Scientist
Suite 900, 475 Howe Street	3650 Wesbrook Mall
Vancouver, British Columbia, Canada  V6C 2B3	Vancouver, British =

Columbia, Canada  V6S 2L2
Tel:  604-689-3923	Fax:  604-684-5854	Tel:  604-222-6646	=

Fax:  604-222-6645

This does not constitute an offer to sell a security.  The information =

contained herein was
provided by the Company and is not guaranteed for accuracy or =

__________________________________________________________________ =

from David G.M. Smith  - WebMaster
Tel (604) 988-6575    Fax (604) 988-6575     Email: dgmsmith at
       WWW Consulting and Internet Business Solutions

More information about the Immuno mailing list